Literature DB >> 28516398

Gynecological brachytherapy for postoperative endometrial cancer: dosimetric analysis (Ir-192 vs Co-60).

V Tormo Ferrero1, R Duque Ugarte2, M Á Berenguer Francés2, R Cardenal Maciá2.   

Abstract

INTRODUCTION: Endovaginal brachytherapy treatment dosimetry differences were studied using Ir-192 or Co-60 sources for postoperative endometrial cancer.
MATERIALS AND METHODS: A prospective descriptive study was conducted. Thirty-six dosimetry plans of different patients were studied (15 by Ir-192 and 21 by Co-60). Variables studied included D2cc Rectum, D2cc Bladder, D2cc Sigmoid, dose percentage at point 0 (applicator surface on the top of the cylinder) and dose percentage at point 1 (5 mm deep on the top of the cylinder). A comparative analysis was performed of the values obtained from each variable between Ir-192 and Co-60 treatments. We compared average of each variables between Iridium and Cobalt by T Student for independent samples (SPSS 22).
RESULTS: There were no significant differences on using Ir-192 or Co-60 by variables, except for dose percentage at point 1 in which we detected significant differences (Table 1). Table 1 The results Variables Sources Iridium 192 Cobalt 60 D2cc Rectum (mean dose) [rank] 6.01 Gy [3.99-7.90] 5.28 Gy [3.87-6,34] D2cc Bladder (mean dose) [rank] 5.82 Gy [4.20-8.38] 5.05 Gy [2.23-6.95] D2cc Sigmoid (mean dose) [rank] 4.43 Gy [1.66-6.67] 2.33 Gy [0.60-4.28] Dose percentage at point 0a (mean) [rank] 210.74% [120.90-234.90] 204.75% [177.10-223] Dose percentage at point 1b (mean) [rank] 93.49% [87.30-100.60] 100.11% [96.70-102] aPoint 0: point to the applicator surface bPoint 1: point to 5 mm applicator surface DISCUSSION: Brachytherapy treatment dosimetry plans are similar using Ir-192 or Co-60, except dose percentage at point 1. In the scientific literature, some differences exist and there are some advantages in using cobalt.

Entities:  

Keywords:  Endometrial cancer; Iridium; Radioisotope brachytherapy

Mesh:

Substances:

Year:  2017        PMID: 28516398     DOI: 10.1007/s12094-017-1670-x

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  5 in total

1.  Comparison of 60cobalt and 192iridium sources in high dose rate afterloading brachytherapy.

Authors:  Jürgen Richter; Kurt Baier; Michael Flentje
Journal:  Strahlenther Onkol       Date:  2008-04       Impact factor: 3.621

2.  Comparison of Axxent-Xoft, (192)Ir and (60)Co high-dose-rate brachytherapy sources for image-guided brachytherapy treatment planning for cervical cancer.

Authors:  P N Mobit; S Packianathan; R He; C C Yang
Journal:  Br J Radiol       Date:  2015-05-21       Impact factor: 3.039

3.  Dosimetric comparison of brachytherapy sources for high-dose-rate treatment of endometrial cancer: (192)Ir, (60)Co and an electronic brachytherapy source.

Authors:  Paul N Mobit; Alex Nguyen; Satyaseelan Packianathan; Rui He; Claus C Yang
Journal:  Br J Radiol       Date:  2016-01-08       Impact factor: 3.039

4.  Treatment planning study of the 3D dosimetric differences between Co-60 and Ir-192 sources in high dose rate (HDR) brachytherapy for cervix cancer.

Authors:  Antony Palmer; Orla Hayman; Sarah Muscat
Journal:  J Contemp Brachytherapy       Date:  2012-03-30

5.  Comparison of (60)Co and (192)Ir sources in HDR brachytherapy.

Authors:  Stefan Strohmaier; Grzegorz Zwierzchowski
Journal:  J Contemp Brachytherapy       Date:  2011-12-30
  5 in total
  2 in total

1.  Intra-cavitary brachytherapy in endometrial carcinoma: experience with cobalt-60 source.

Authors:  Jose Antonio Domínguez Rullán; María Teresa Muñoz Miguelañez; Rafael Colmenares Fernández; Miguel Cámara Gallego; Mercedes Martín Sánchez; Feliciano García Vicente; Sonsoles Sancho García
Journal:  J Contemp Brachytherapy       Date:  2022-05-10

Review 2.  Comparative Analysis of 60Co and 192Ir Sources in High Dose Rate Brachytherapy for Cervical Cancer.

Authors:  Aiping Wen; Xianliang Wang; Bingjie Wang; Chuanjun Yan; Jingyue Luo; Pei Wang; Jie Li
Journal:  Cancers (Basel)       Date:  2022-09-29       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.